Short Interest Update on Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN) : The traders have covered their outstanding shorts in Regeneron Pharmaceuticals (REGN) to the tune of -4,961 shares, a change of -0.1%. As on Jul 29, 2016, the outstanding shorts on the stock were 3,631,436 shares, however, by August 15, 2016, the shorts had reduced to 3,626,475 shares. The covering shows that the traders dont believe that a large downside exists in the stock from current levels. The open short positions equal 4.7% of the free float of the stock. It takes 4 days to cover the outstanding short positions. The stock has an average daily volume of 884,030 shares. The short interest information was released on Wednesday Aug 24th after the market close.

Regeneron Pharmaceuticals (NASDAQ:REGN): The stock opened at $419.61 on Wednesday but the bulls could not build on the opening and the stock topped out at $424.95 for the day. The stock traded down to $403.50 during the day, due to lack of any buying support eventually closed down at $405.25 with a loss of -3.65% for the day. The stock had closed at $420.61 on the previous day. The total traded volume was 605,113 shares.


In a related news, Goldstein Joseph L, director of Regeneron Pharmaceuticals Inc, unloaded 2,125 shares at an average price of $425 on July 29, 2016. The total amount of the transaction was worth $903,125, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.